SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Taha Roodbar Shojaei, Meisam Tabatabaei, Sherif Shawky, Mohamad Amran Mohd Salleh, Dirk Bald, A review on emerging diagnostic assay for viral detection: the case of avian influenza virus, Molecular Biology Reports, 2014,

    CrossRef

  2. 2
    Ping Lu, Holger Lill, Dirk Bald, ATP synthase in mycobacteria: Special features and implications for a function as drug target, Biochimica et Biophysica Acta (BBA) - Bioenergetics, 2014, 1837, 7, 1208

    CrossRef

  3. 3
    Lici A. Schurig-Briccio, Takahiro Yano, Harvey Rubin, Robert B. Gennis, Characterization of the type 2 NADH:menaquinone oxidoreductases from Staphylococcus aureus and the bactericidal action of phenothiazines, Biochimica et Biophysica Acta (BBA) - Bioenergetics, 2014, 1837, 7, 954

    CrossRef

  4. 4
    Anil Koul, Luc Vranckx, Neeraj Dhar, Hinrich W.H. Göhlmann, Emre Özdemir, Jean-Marc Neefs, Melanie Schulz, Ping Lu, Ejvind Mørtz, John D. McKinney, Koen Andries, Dirk Bald, Delayed bactericidal response of Mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism, Nature Communications, 2014, 5,

    CrossRef

  5. 5
    Geoffrey Burnstock, Jean-Marie Boeynaems, Purinergic signalling and immune cells, Purinergic Signalling, 2014, 10, 4, 529

    CrossRef

  6. 6
    Disha Awasthy, Anisha Ambady, Ashwini Narayana, Sapna Morayya, Umender Sharma, Roles of the two type II NADH dehydrogenases in the survival of Mycobacterium tuberculosis in vitro, Gene, 2014, 550, 1, 110

    CrossRef

  7. 7
    Margarida Duarte, Ana M. Tomás, The mitochondrial complex I of trypanosomatids - an overview of current knowledge, Journal of Bioenergetics and Biomembranes, 2014, 46, 4, 299

    CrossRef

  8. 8
    Dirk Bald, Anil Koul, Advances and strategies in discovery of new antibacterials for combating metabolically resting bacteria, Drug Discovery Today, 2013, 18, 5-6, 250

    CrossRef

  9. 9
    A. J. Warman, T. S. Rito, N. E. Fisher, D. M. Moss, N. G. Berry, P. M. O'Neill, S. A. Ward, G. A. Biagini, Antitubercular pharmacodynamics of phenothiazines, Journal of Antimicrobial Chemotherapy, 2013, 68, 4, 869

    CrossRef

  10. 10
    Elena Mashkovtseva, Stanislav Boronovsky, Yaroslav Nartsissov, Combined mathematical methods in the description of the FoF1-ATP synthase catalytic cycle, Mathematical Biosciences, 2013, 243, 1, 117

    CrossRef

  11. 11
    A.C. Haagsma, P. Lu, H. Lill, D. Bald, The interaction of the diarylquinoline TMC207, a new tuberculosis antibiotic, with its target mycobacterial ATP synthase, Biochimica et Biophysica Acta (BBA) - Bioenergetics, 2012, 1817, S14

    CrossRef

  12. 12
    L. J. Alderwick, G. S. Lloyd, A. J. Lloyd, A. L. Lovering, L. Eggeling, G. S. Besra, Biochemical characterization of the Mycobacterium tuberculosis phosphoribosyl-1-pyrophosphate synthetase, Glycobiology, 2011, 21, 4, 410

    CrossRef

  13. 13
    Takushi Kaneko, Christopher Cooper, Khisimuzi Mdluli, Challenges and opportunities in developing novel drugs for TB, Future Medicinal Chemistry, 2011, 3, 11, 1373

    CrossRef

  14. 14
    Stewart T Cole, Giovanna Riccardi, New tuberculosis drugs on the horizon, Current Opinion in Microbiology, 2011, 14, 5, 570

    CrossRef

  15. 15
    Julian G. Hurdle, Alex J. O'Neill, Ian Chopra, Richard E. Lee, Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections, Nature Reviews Microbiology, 2011, 9, 1, 62

    CrossRef

  16. 16
    Anil Koul, Eric Arnoult, Nacer Lounis, Jerome Guillemont, Koen Andries, The challenge of new drug discovery for tuberculosis, Nature, 2011, 469, 7331, 483

    CrossRef

  17. 17
    Xiaoqian Wu, Julian G. Hurdle, The Membrane as a Novel Target Site for Antibiotics to Kill Persisting Bacterial Pathogens,